Global, Regional, and National Burden of Alopecia Areata in Children and Adolescents Aged 0-19 Years from 1990 to 2021 and Projection to 2040

Vitamin D may help reduce severity and relapse of alopecia areata.

Janus kinase inhibitors are the most supported treatment for pediatric alopecia areata, while other options have limited evidence.

Alopecia areata cases have increased globally, affecting mostly women aged 30-34, with links to other health issues.

Alopecia areata affects 1 in 50 people, with non-White ethnic groups experiencing the most impact on mental health and work.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

The Middle East and Africa need better data, treatment consensus, and support for Alopecia Areata.

Alopecia areata and its severe forms are becoming more common, especially among females, adults, and people in the Northeast.

Cases of alopecia areata and its impact on life quality rose globally, but when adjusted for age, the rates decreased, especially in poorer regions.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

People with alopecia areata often have other health issues like skin diseases, metabolic syndrome, stomach infections, lupus, anemia, thyroid problems, mental health issues, vitamin D deficiency, and hearing and eye problems.

Alopecia areata patients often have low vitamin D levels.

Adequate vitamin D is crucial for skin health and should be considered in dermatology.

People with alopecia areata often have lower levels of vitamin D, zinc, and folate, but more research is needed to understand if supplements can help treat it.